MDT

87.35

-1.13%↓

115.39

-0.45%↓

VEEV

151.19

-4.01%↓

HQY

79.95

-3.83%↓

TLRY

6.57

-3.67%↓

MDT

87.35

-1.13%↓

115.39

-0.45%↓

VEEV

151.19

-4.01%↓

HQY

79.95

-3.83%↓

TLRY

6.57

-3.67%↓

MDT

87.35

-1.13%↓

115.39

-0.45%↓

VEEV

151.19

-4.01%↓

HQY

79.95

-3.83%↓

TLRY

6.57

-3.67%↓

MDT

87.35

-1.13%↓

115.39

-0.45%↓

VEEV

151.19

-4.01%↓

HQY

79.95

-3.83%↓

TLRY

6.57

-3.67%↓

MDT

87.35

-1.13%↓

115.39

-0.45%↓

VEEV

151.19

-4.01%↓

HQY

79.95

-3.83%↓

TLRY

6.57

-3.67%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

4.41 3.28

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.16

Max

4.41

Galvenie mērījumi
By Trading Economics
Ienākumi	-12M -27M
Pārdošana	-5.3M 663K
P/E Sektora vidējais	22.5 66.418
Peļņas marža	-3,998.492
Darbinieki	69
EBITDA	-13M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+221.65% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-193M 951M
Iepriekšējā atvēršanas cena	1.13
Iepriekšējā slēgšanas cena	4.41

Ziņu noskaņojums

By Acuity

50%

161 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026. g. 9. apr. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 9. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. apr. 23:07 UTC

Tirgus saruna

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026. g. 9. apr. 22:54 UTC

Tirgus saruna

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026. g. 9. apr. 20:57 UTC

Galvenie ziņu notikumi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. apr. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026. g. 9. apr. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026. g. 9. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. apr. 19:30 UTC

Galvenie ziņu notikumi

How Digital Currencies Have Helped Iran -- WSJ

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

221.65% augšup

Prognoze 12 mēnešiem

Vidējais 13.67 USD 221.65%

Augstākais 17 USD

Zemākais 11 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

161 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.